Lupin launches oral antibiotic Solosec in US
New Delhi: Drug major Lupin said it has launched Solosec, an oral antibiotic used in treating bacterial vaginosis (BV) in women, in the US market.
The company has launched Solosec oral granules in the American market after having received approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
With more than four million women treated for BV in the US annually, and only 50 percent completing 5 to 7-day treatments, there is a clear need for an effective, single-dose oral treatment, Lupin Chief Executive Officer Vinita Gupta said in a statement.
According to the company, it only takes one packet of Solosec to complete treatment and the single dose stays in the body and continues to treat BV for four days without an alcohol restriction.
Solosec does not inhibit the enzyme that metabolises alcohol, it added.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd